Clinical Trials Logo

GI Carcinoma clinical trials

View clinical trials related to GI Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04931420 Not yet recruiting - Lung Cancer Clinical Trials

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Start date: September 30, 2025
Phase: Phase 2
Study type: Interventional

This study is designed for participants who have cancer of the upper gastrointestinal (GI) tract such as cancer of the esophagus, stomach, duodenum (the initial portion of your small intestine), pancreas, bile duct (Cholangiocarcinoma), ampulla, or gall bladder with limited sites of spread (metastases). Doctors leading this study are looking to see if treating the disease using sequential procedures (more than one procedure given one after another) such as surgeries or radiation can lead to better survival and if these surgeries, combined with standard of care treatment, are safe for the treatment of upper GI cancers.

NCT ID: NCT04789200 Completed - GI Disorders Clinical Trials

Phase 2 Study of NX9 for Delineation of Bowel Anatomy

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

This study will evaluate marking and distention of the bowel of the oral contrast agent, NX9, at CT of the abdomen and pelvis, VLDCT with no contrast will be followed by VLDCT with NX9 contrast followed by CT with NX9 and standard IV contrast. Eligible subjects will have cancer or other GI disorders for which CT is typically used to assess their disease. This is an open label study with efficacy evaluated in a masked fashion following completion of the entire study. Results of the NX9 scans will not be used for treatment decisions. PK will be evaluated in a subset of subjects at a single center.